GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » YoY EBITDA Growth

Lipella Pharmaceuticals (Lipella Pharmaceuticals) YoY EBITDA Growth : 11.89% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Lipella Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 11.89%.

Lipella Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was $-0.16.


Lipella Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Lipella Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals YoY EBITDA Growth Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
- -3,500.00 -96.60 -20.41

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.53 -96.32 -85.48 -61.90 11.89

Lipella Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Lipella Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.767--0.637)/ | -0.637 |
=-20.41 %

Lipella Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-0.163--0.185)/ | -0.185 |
=11.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipella Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipella Pharmaceuticals (Lipella Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.
Executives
Lori Birder director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman director, 10 percent owner, officer: See Remarks C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston officer: Chief Financial Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor director, 10 percent owner, officer: Chief Medical Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208